Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim is fully supported by the provided FDA label excerpts (sections 5.1, 4, 17, 13.1, and 6) with no contradictions identified.
Category Scores
Accurate Statements
MOUNJARO/tirzepatide causes thyroid C-cell tumors in rats.
Section 5.1: dose- and treatment-duration-dependent increase in thyroid C-cell tumors (adenomas and carcinomas) in rats.
The human relevance of the rodent thyroid C-cell tumor finding is unknown/not determined.
Section 5.1: 'It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans...' and Section 17: human relevance has not been determined.
MOUNJARO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
Section 4: contraindicated in personal/family history of MTC or MEN 2.
Patients should be counseled to report symptoms of thyroid tumors (e.g., neck lump, persistent hoarseness, dysphagia, dyspnea).
Section 5.1: counsel regarding potential risk and inform of symptoms; Section 17: report symptoms including a lump in the neck, persistent hoarseness, dysphagia, or dyspnea.
Risk of thyroid C-cell tumors is described in the prescribing information as a serious adverse reaction.
Section 6: lists 'Risk of Thyroid C-Cell Tumors' among serious adverse reactions described.
Carcinogenicity findings include increased thyroid C-cell adenomas (and adenomas/carcinomas combined).
Section 13.1: statistically significant increase in thyroid C-cell adenomas; combined adenomas and carcinomas observed.
Unsupported Statements
Contradictions
Important Omissions
The AI response does not explicitly mention the label’s additional counseling/monitoring details in section 5.1 (e.g., routine calcitonin/thyroid ultrasound monitoring of uncertain value and further evaluation steps if calcitonin is elevated or nodules are present).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The core safety-related claims made (rodent thyroid C-cell tumors; human relevance unknown; contraindications for MTC/MEN 2; symptom counseling; inclusion as a serious adverse reaction) are on-label. Omission is limited to detailed monitoring/next-step guidance rather than core contraindication/counseling.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing the label’s specific monitoring/uncertain value language for routine serum calcitonin and thyroid ultrasound, and the label’s further evaluation guidance if abnormalities are found.
Suggested Improvement
Add section 5.1 specifics: routine calcitonin/thyroid ultrasound monitoring is of uncertain value; explain potential for unnecessary procedures due to low specificity/high background incidence; and state that elevated calcitonin or thyroid nodules should prompt further evaluation.